Development and Testing of a 212Pb/212Bi Peptide for Targeting Metastatic Melanoma (Final Report)
- Pacific Northwest National Laboratory (PNNL), Richland, WA (United States)
The purpose of this project is to develop a new radiolabeled peptide for imaging and treating metastatic melanoma. The immunoconjugate consists of a receptor-specific peptide that targets melanoma cells. The beta-emitter lead-212 (half-life = 10.4 hours) is linked by coordination chemistry to the peptide. After injection, the peptide targets melanoma receptors on the surfaces of melanoma cells. Lead-212 decays to the alpha-emitter bismuth-212 (half-life = 60 minutes). Alpha-particles that hit melanoma cell nuclei are likely to kill the melanoma cell. For cancer cell imaging, the lead-212 is replaced by lead-203 (half-life = 52 hours). Lead-203 emits 279 keV photons (80.1% abundance) that can be imaged and measured for biodistribution analysis, cancer imaging, and quantitative dosimetry.
- Research Organization:
- Pacific Northwest National Laboratory (PNNL), Richland, WA (United States); V.G. Khlopin Radium Institute, St. Petersburg (Russia Federation); AlphaMed, Inc., Acton, MA (United States); AlphaMed, Inc., Victoria, BC (Canada); Univ. of Missouri, Columbia, MO (United States)
- Sponsoring Organization:
- USDOE
- DOE Contract Number:
- AC05-76RL01830;
- OSTI ID:
- 1054055
- Report Number(s):
- PNNL--21943; NN4010021
- Country of Publication:
- United States
- Language:
- English
Similar Records
Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
Patent
·
Tue Apr 23 00:00:00 EDT 2019
·
OSTI ID:1568221
Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
Patent
·
Tue Jul 19 00:00:00 EDT 2016
·
OSTI ID:1531922
Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
Patent
·
Tue Nov 02 00:00:00 EDT 2021
·
OSTI ID:1860015